Related Experiment Video
Updated: Feb 19, 2026
05:14
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
4.7K
Dopamine System Dysregulation in Major Depressive Disorders
Pauline Belujon1, Anthony A Grace2
1INSERM, U1084, Poitiers, France; University of Poitiers, U1084, Poitiers, France.
The International Journal of Neuropsychopharmacology
|November 7, 2017
Summary
Major depressive disorder involves anhedonia, linked to dopamine system deficits. This review examines how brain circuits regulate dopamine and impact depression, including effects of agomelatine and ketamine.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Anhedonia is a core symptom of major depressive disorder (MDD).
- The dopamine system is crucial for hedonic processing and is implicated in MDD's anhedonia.
- Dopaminergic activity is regulated by brain structures like the hippocampus and amygdala.
Purpose of the Study:
- To review the afferent modulation of the dopamine system in relation to MDD.
- To explore the origins of dopaminergic deficits in depression.
- To discuss the effects of novel antidepressants (agomelatine, ketamine) on the dopamine system.
Main Methods:
- Literature review of basic and clinical studies.
- Analysis of research on brain circuit regulation of dopamine.
- Examination of antidepressant mechanisms.
Main Results:
- Depression is associated with dopaminergic system deficits.
- Dysregulation in afferent regulatory circuits likely causes these deficits.
- Novel antidepressants like agomelatine and ketamine show system-level effects.
Conclusions:
- Understanding afferent modulation of the dopamine system is key to MDD.
- Targeting regulatory circuits may offer new therapeutic strategies for depression.
- Agomelatine and ketamine represent promising avenues for treating anhedonia in MDD.
Related Concept Videos
01:18Depression: Overview
973
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
973
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
2.1K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.1K
01:23Antidepressant Drugs: MAOIs and Other Agents
975
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
975
01:29Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
01:27Depressive Disorders: Etiology
748
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
748
01:27Depressive Disorders: MDD and Dysthymia
858
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
858